Answers are grounded in this paper and cite their sources.
• The role of regulatory T cells (Tregs) in self-tolerance has become clear in recent years following the award of the Nobel prize in 2025.• Tregs contribute to immune self-tolerance and maintain tissue homeostasis; adding a chimeric antigen receptor (CAR) confers greater specificity and efficacy, according to early trials.• The development of therapeutic Tregs represents an important addition to the exciting field of immune modulation.The capacity of the immune system to defend its host against a vast array of microorganisms while avoiding auto-aggressive responses is an extraordinary feat. This is particularly remarkable given that the proteins of a pathogen are not categorically different from those of the host. Over recent decades it has become clear that this feat results from both deletion of self-reactive cells in the thymus and regulation of rogue T cells in the periphery. The 2025 Nobel Prize in Physiology or Medicine was awarded for the discovery of naturally occurring regulatory T cells (Tregs), the specialized T-cell population now recognized as central to peripheral tolerance.In rat and mouse models, it had long been observed that immune tolerance could be transferred by the injection of T cells from a tolerant animal to a naïve animal (Qin et al. 1993). The cellular basis of this phenomenon became clearer through the work of Sakaguchi, Ramsdell, and Brunkow, who identified a thymus-derived lineage of cells expressing the key transcription factor forkhead box P3 (FOXP3).The working assumption is that thymically selected Tregs, specific for a variety of autoantigens, patrol the peripheral immune system and are called into play when tissue inflammation is triggered by an invading pathogen. The subset of Tregs that sustains selftolerance in such situations is assumed to be those specific for the autoantigens expressed by the tissue in question. Given the phenomena of linked and bystander suppression, it is remarkable that Tregs allow the immune response against the invading pathogen to proceed while inhibiting any autoreactive T cells that arrive on the scene.It has become increasingly clear that Tregs not only prevent autoreactive responses, but also play an important role in tissue repair and homeostasis. Tregs are heterogenous in phenotype and function, and they circulate and localize in different tissues (Lui et al. 2020). They respond to changes in their tissue microenvironment by modulating inflammatory responses and maintaining tissue homeostasis (Dikiy et al. 2023). However, it remains unclear precisely how Tregs respond to tissue damage or influence tissue fibrosis.In their Frontiers in Science lead article, Bluestone and colleagues outline the scientific and translational advances that are bringing the therapeutic use of Tregs closer to a clinical reality (Bluestone et al. 2026). There is undoubtedly a substantial unmet clinical need for better means of suppressing unwanted immune responses in autoimmunity and organ transplantation. Pharmacological immunosuppressive drugs are effective in many settings, but are accompanied by multiple side effects, including increased incidence of cancer and opportunistic infections. In other disorders, such as severe rheumatoid arthritis and systemic sclerosis , these drugs provide limited benefit and there is paucity of treatment options. The therapeutic potential of Tregs is being explored in a rapidly evolving field. In early clinical experiments, use of polyclonal Tregs in kidney and liver transplant recipients was shown to be safe, with some tantalizing hints of efficacy in dampening the rejection response (Sawitzki et al. 2020). However, animal models demonstrated that conferring alloantigen specificity on the injected Tregs substantially increased their potency (Sagoo et al. 2011;MacDonald et al. 2016). A very recent Phase 1/2 trial of alloantigen-specific Tregs in human transplant recipients yielded partial success in achieving operational tolerance (Quell therapeutics 2026). According to interim results, following injection of Tregs expressing a chimeric antigen receptor (CAR) specific for a donor human leukocyte antigen (HLA), several liver transplant recipients were weaned off their calcineurin inhibitor immunosuppressive therapy and maintained good transplant function on low levels of everolimus alone. Nonetheless, when the final low dose of immunosuppression was withdrawn, rejection ensued. This highlights an important point: Tregs are designed to control low-frequency autoimmune responses, but asking them to manage responses against HLA alloantigens, which are orders of magnitude higher in frequency, is a very tall order.Although immune tolerance has yet to be achieved, early clinical experiments have shown the potential for therapeutic Tregs to overcome several important translational challenges. They can persist in the body for at least 1 year after injection and concentrate at the site of the relevant target antigen (e.g., the transplanted liver) -thereby providing levels sufficient allow minimisation of immunosuppressive drugs. They can also retain a pristine phenotyperesembling native Tregs as judged by their surface markers and transcriptional profile, which is important for their function and safety.These observations suggest that the therapeutic use of Tregs has a bright future in the context of autoimmune and inflammatory diseases. Preliminary results were recently reported from a small Phase 1 study of CAR-Tregs specific for citrunillated proteins, which are highly expressed in patients with rheumatoid arthritis (Minna et al. 2025). Treatment led to rapid improvements in symptoms and reduced joint inflammation. Although these effects were temporary, they indicate the possible benefits of this approach.In certain autoimmune diseases, CAR) effector T cells with specificity for autoreactive B cells have generated intense interest. The first trial of this approach was reported in 2022 in patients with systemic lupus erythematosus (Mackensen et al. 2022) and has spawned several subsequent trials in related diseases. These successes are paralleled by the use of bi-specific T-cell engagers that harness the lytic function of T cells to kill autoreactive B cells. While these examples illustrate promising categories of therapeutics, even more may be gained by deploying Tregs, as opposed to T effectors, to target autoreactive cells such as B cells.Further trials (e.g. NCT07473154) are targeting Tregs to the sites of immune activation in both lymphoid and peripheral tissues, aiming not only to arrest the immune response, but also to help restore tissue homeostasis. This approach capitalises on the ability of Tregs to mediate "bystander effects", calming pro-inflammatory monoytes and even inhibiting fibroblast activation.The development of therapies that manipulate the immune system is one of the most exciting advances in modern medicine. The harnessing of Tregs, and directing their attention to sites of autoimmune, alloimmune and inflammatory responses-as highlighted by Bluestone et al. (Bluestone et al. 2026)-represents an important addition to this field.
No takes yet. Share an insight, caveat, or question.
Lombardi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: